These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36484152)

  • 1. Quantitative assessment of botulinum toxin injection on blink rate in blepharospasm.
    Yazdanpanah G; Yen MT; Pflugfelder SC
    Orbit; 2023 Dec; 42(6):571-578. PubMed ID: 36484152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects.
    Mitsikostas DD; Dekundy A; Hanschmann A; Althaus M; Scheschonka A; Pagan F; Jankovic J
    Curr Med Res Opin; 2021 Oct; 37(10):1761-1768. PubMed ID: 34384301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Videonystagmography as a tool to assess blepharospasm before and after botulinum toxin injection.
    Casse G; Adenis JP; Sauvage JP; Robert PY
    Graefes Arch Clin Exp Ophthalmol; 2008 Sep; 246(9):1307-14. PubMed ID: 18581129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.
    Truong DD; Gollomp SM; Jankovic J; LeWitt PA; Marx M; Hanschmann A; Fernandez HH;
    J Neural Transm (Vienna); 2013 Sep; 120(9):1345-53. PubMed ID: 23435927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
    Horwath-Winter J; Bergloeff J; Floegel I; Haller-Schober EM; Schmut O
    Br J Ophthalmol; 2003 Jan; 87(1):54-6. PubMed ID: 12488263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin and blink rate in patients with blepharospasm and increased blinking.
    Ferrazzano G; Conte A; Fabbrini G; Bologna M; Macerollo A; Defazio G; Hallett M; Berardelli A
    J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):336-40. PubMed ID: 24963123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of eyelid botulinum toxin injection on lacrimal drainage.
    Sahlin S; Chen E; Kaugesaar T; Almqvist H; Kjellberg K; Lennerstrand G
    Am J Ophthalmol; 2000 Apr; 129(4):481-6. PubMed ID: 10764857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blink index as a response predictor of blepharospasm to botulinum neurotoxin-A treatment.
    Jang J; Lew H
    Brain Behav; 2021 Nov; 11(11):e2374. PubMed ID: 34555267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
    Park DI; Shin HM; Lee SY; Lew H
    Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
    Evidente VG; Truong D; Jankovic J; Comella CL; Grafe S; Hanschmann A
    J Neurol Sci; 2014 Nov; 346(1-2):116-20. PubMed ID: 25186131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IncobotulinumtoxinA for the Treatment of Blepharospasm in Toxin-Naïve Subjects: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial.
    Mitsikostas DD; Dekundy A; Sternberg K; Althaus M; Pagan F
    Adv Ther; 2020 Oct; 37(10):4249-4265. PubMed ID: 32779096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.
    Jankovic J; Comella C; Hanschmann A; Grafe S
    Mov Disord; 2011 Jul; 26(8):1521-8. PubMed ID: 21520284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex, blinking, and dry eye.
    Culoso A; Lowe C; Evinger C
    J Neurophysiol; 2020 Feb; 123(2):831-842. PubMed ID: 31940243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, placebo-controlled, crossover clinical trial of super blue-green algae in patients with essential blepharospasm or Meige syndrome.
    Vitale S; Miller NR; Mejico LJ; Perry JD; Medura M; Freitag SK; Girkin C
    Am J Ophthalmol; 2004 Jul; 138(1):18-32. PubMed ID: 15234278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tear osmolarity, dry eye syndrome, blepharospasm and botulinum neurotoxin.
    Girard B; de Saint Sauveur G
    J Fr Ophtalmol; 2021 Dec; 44(10):1553-1559. PubMed ID: 34756743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment.
    Hosotani Y; Yokoi N; Okamoto M; Ishikawa H; Komuro A; Kato H; Mimura O; Gomi F
    Jpn J Ophthalmol; 2020 Jan; 64(1):45-53. PubMed ID: 31823132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrical activation of the orbicularis oculi muscle does not increase the effectiveness of botulinum toxin type A in patients with blepharospasm.
    Conte A; Fabbrini G; Belvisi D; Marsili L; Di Stasio F; Berardelli A
    Eur J Neurol; 2010 Mar; 17(3):449-55. PubMed ID: 19968711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the injection botulinum toxin A in cases of blepharospasm syndrome, hemifacial spasm and Meige's syndrome.
    Bastola P; Chaudhary M; Agrawal JP; Shah DN
    Kathmandu Univ Med J (KUMJ); 2010; 8(31):305-10. PubMed ID: 22610735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm.
    Chundury RV; Couch SM; Holds JB
    Ophthalmic Plast Reconstr Surg; 2013; 29(3):205-7. PubMed ID: 23552607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.